Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

Slide Presentation of the 2007 Annual Meeting of AHRQ

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.


The Statins

Text Description is below the image.
  • Introduction of generics: changing marketplace
  • Huge stakes: $8 billion for Medicare beneficiaries alone
  • Major health consequences of greater affordability

Notes:

Statins is the category that is has the most consistently high level of user interest.
It is the category that probably has the largest potential savings, on a national basis, from switching to more cost-effective drugs.
Recent generic availability of Zocor/simvastatin, key factor.
National potential savings huge
Health consequences are huge as well: drug more affordable for more who need them.
Recently released an analysis of the market trends showing the increase in sales of newly available generic statins.
Stakes are high!


Previous Slide Previous Slide         Contents         Next Slide Next Slide


 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care